<<If the FDA grants interchangeable status on a given FoB product, a duopoly with high pricing and a substantial market share for BAX/MNTA will likely ensue>>
And by your estimation, what are the odds this scenario comes to fruition? Previously on this board you have said that if they do achieve it, it would be "the greatest achievement in biotech history". So that amounts to what, 5-10 chance? IOW, 90-95% chance of failure?
Might be a clue as to why MNTA's market cap has remained frozen for such a long period. Outside of RMF, there is little confidence it will actually happen
Market Data 
Markets 
AI
